Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years old
- People who have locally advanced, spreading, or returning pancreatic cancer, where a specific protein called eGR1 has been found at certain levels on the cancer cells through laboratory testing, and whose cancer has not responded to standard treatment, or who were unable to tolerate it, or who have chosen not to have it
- People who have at least one tumour that can be measured using standard imaging scans
- People who have not received any cancer treatment for at least 4 weeks before joining
- People whose general health and ability to carry out daily activities falls within an acceptable range (rated 0–2 on a standard medical scale)
- People who are expected to live for more than 12 weeks
- People whose blood test results show that their immune cells, red blood cells, and platelets are at or above the required levels
- People whose liver and kidney function blood test results fall within the required ranges
- People who are willing to take part and agree to sign a consent form
Who may not be able to join:
- People whose cancer has spread to the brain or central nervous system
- People who have previously received a type of cancer treatment that uses modified immune cells taken from a donor or the patient (adoptive cell therapy)
- People who have any active infection that is not under control, including hepatitis B, hepatitis C, HIV, or syphilis
- People who have received a live vaccine within the past 3 months
- People with a history of a weakened immune system
- People with an active autoimmune disease (where the immune system attacks the body's own tissues)
- People who have regularly been taking steroid medications at higher than a low specified dose within the 2 weeks before screening
- People with serious heart, lung, digestive, metabolic, or blood pressure conditions, including but not limited to: previous heart bypass or stent procedures, recent heart attack or unstable chest pain, significant heart failure, reduced heart pumping ability, poorly controlled blood pressure, certain heart rhythm problems, serious lung disease, poorly controlled diabetes, or serious bowel conditions such as major bleeding, severe diarrhoea, or blockages requiring intervention
- People who are known to be allergic or have a medical reason that would make the study treatment unsafe for them
- People who are pregnant or breastfeeding
- People with a history of neurological or mental health conditions
- People considered unsuitable for the trial for any other reason, as determined by the trial doctor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhuan Liao, Changhai Hospital
Phone: +86-13124828854
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (TESAE); Number of participants with abnormal clinical laboratory parameters reported as TEAE; Number of participants with abnormal vital signs reported as TEAE; Number of participants with change from baseline in QT/QTc interval in electrocardiogram
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.